- March 2019
- December 2018
- June 2018
- January 2018
- December 2017
- October 2017
- June 2017
- April 2017
- February 2017
- January 2017
- December 2016
- September 2016
- August 2016
- June 2016
- March 2016
- February 2016
- January 2016
- December 2015
- October 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- February 2014
- January 2014
- December 2013
- November 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
Category Archives: Opioid
Opioid addiction and misuse has been around since the earliest civilizations. Certainly when I graduated from Dalhousie College of Pharmacy 24 years ago and started working as a Pharmacist in Baddeck, we were all aware of such addiction. Based on what we were taught at the time, anyone who took an opioid dose of only the required amount for their pain and no more, would almost certainly avoid opioid misuse. This theory, largely fed to the medical community by the industry making these medications, has now proven to be untrue. The corporate deception has gone as far as to be prosecuted at a criminal level. Based on our centuries of using this class of medication it’s really a wonder it took us this long to figure out the truth. Although the story behind that deception is too long to go into here, one thing is for sure, the opioid epidemic which has been gradually marching entirely across this continent eastward has become one of the most urgent medical crises of our time.
A few years ago I became involved with a group of medical professionals concerned with this topic called the Atlantic Mentorship Network, which has a focus on pain and addiction. It has turned out to be the best alignment in my career. Headed by Dr.’s Peter MacDougall and John Fraser, it is undeniably the best resource for anyone in working with pain or addiction treatment. They recently held a one day conference in September in Inverness that focused on the Challenges and Opportunities in the Delivery of Pain & Addiction Care in Rural Communities. Held this year at the beautiful Inverness County Centre for the Arts, it was a great collection of a dozen speakers that really educated and inspired those in attendance to take back to work helping those with pain and addiction and preventing addiction. All did an amazing job at educating from their own standpoint of doctor, pharmacist, counselor or Nurse.
Without a doubt, the absolute highlight of the day for me came not from any healthcare professional, but from a guest invited to speak on the topic of addiction by the name of John MacDonald. Accompanied by Laura Chapman MPH and Chera Clements RN, John quietly and modestly approached the podium as undoubtedly the bravest person in the room. Not used to speaking in front of the 60 plus people that were in attendance, he stated his name and openly announced himself as a recovering drug addict. John spoke for about 10 minutes, which probably seemed like an eternity for him. Little did he know the grasp he had on this group. In a day filled with Powerpoint presentations and laser pointers, he quietly stood in front of a group of strangers holding a hand written note in a simple scribbler and delivered an address that I don’t think I’ll ever forget. It took an experience like this to reinforce to me that the few brief interactions with patients I see every day at my work who have addiction issues did not choose to become that way. I later asked Laura for a transcript of his presentation so I could include it in the words he wrote with his permission, which he was happy to supply
. Without this, most of his effect would have been lost here. In listening and watching him that day, I was reminded of my own healthy children and how easily it is to have your life nearly destroyed by opioids. Remember that rescue Naloxone kits are provided free from pharmacies in Nova Scotia. If you are misusing opioids or are in regular contact with someone that is, you owe it to yourself to have a kit and learn how to use it. It may almost certainly help save a life.
Here is a transcript of John’s presentation:
Hello Everyone. My name is John MacDonald. I’ve been asked to speak to you today about substance abuse and addiction.
I’ve been using drugs since I was 13 years old. And in that 17 year period, myself, as well as our communities, went through different drug fads. First – it was cannabis, LSD, mushrooms, ecstasy and amphetamines and any other upper available. Then when I was 14, I started using oxys, cocaine, and crystal meth when available. Not all that long after, I found myself physically dependent on oxycontin and at that point, I had no idea what I was going through. I was never told before you could get sick without it. After a few days of waking up sick but getting better after I used, I googled side effects of oxys and that’s how I learned I was physically dependent. When I was a teen, we never learned about this kind of staff and never had programs at school geared toward drug prevention.
I started injecting drugs around the age of 15 and pretty soon, my addiction became even more out of control. I found myself becoming someone I couldn’t recognize. You see I didn’t set out wanting to become addicted to drugs or to be a junkie. No one does. It happens slowly over time. I experienced a lot of trauma in my early life and because it offered an escape from the horror of my home and public life while I was high nothing or no one could hurt me. However, after a while, it did more harm than good. Even today, I’m trying to reverse the damage drug addiction and substance abuse caused as I’m sure I will always have to do the rest of my life.
I spent years in and out of Detox but because I was there so often, when I would go, they would fast track me and turn a short time even shorter. I’d be discharged in the first week often leaving in withdrawal, which in turn would make my decision to use easy. The times I managed to stay off drugs for a few days after getting out, I would have everyone I used with constantly offering me free drugs and dealers calling trying to get me to use free stuff. They did it because they couldn’t clean up so they didn’t want me to but, whatever the reason, I always ended up giving in.
Drugs took everything from me, my dignity, health, family and friends. It made me homeless, sleeping under stairs, in ditch coverts, on benches. I even slept under the band shell in New Waterford one winter but more importantly, it made me lose myself and my love for myself and my happiness as it does and will continue to do to anyone that comes in contact with these substances.
Over the past 17 years, I have overdosed more than 20 times. I’ve witnessed more than anyone would be able to comprehend and I just lost my 28th friend from an overdose.
The Naloxone training program, I feel, is a god send because there are people alive today that probably wouldn’t be if Naloxone wasn’t readily available. I, myself, administered Naloxone on two separate occasions. The friends of those individuals were too scared to call 911 because they thought they would get arrested or in trouble with the police in other ways, so a person there knew I had a kit so he called me. I feel everyone who uses opiates should carry one and if someone you live with or a loved one uses them, you should also have one at hand in case they are using alone and overdose then you would be trained to administer the life-saving injection.
Anyway, thank you for listening and I hope you all have a great day.
This was followed by the largest round of applause we had heard all day, not to mention some encouraging support during his talk from those in attendance. Thanks again John for your insightful words and the best of luck with your future, which I am thinking might result in more than a few saved lives if he continues appearances such as this one.
Graham MacKenzie Ph.C.
I have seen many changes happen to pharmacy in the last 24 years. One of the most career-shifting has been the change in the reimbursement model that has forced pharmacy to revisit how it makes money to remain afloat while continuing the important work of patient care. The traditional work I am referring to is not something that carries the business for most independent pharmacies.
Even before this adjustment to our financial model, we were criticized for not charging for other everyday services. Now, not only are many of us leaving money on the table for uncharged services that would easily have been charged by other professions and accepted by the public, but we are charging for dispensary services in unsustainable ways that fail to reimburse the business. Specialty services like methadone, travel clinics, injections, med reviews, compounding, nursing home filling, and others have helped relieve some of the financial strain on some pharmacy businesses. Some day soon I am sure medical marijuana will be one of those services.
Take two of these programs: methadone and medical marijuana. One currently runs in many Canadian pharmacies and one is on the horizon. Both of these have and will continue to gain popularity for the pain patient that has been prescribed opioids. In the case of methadone, it becomes a specialty rescue plan to give the patient back at least a small part of normalcy, even if there is no projected hard endpoint in sight. It can allow patients to stay off of street drugs and steer away from opioid addiction, and in addition keep their family, hold a job (at least one that allows them to go for a witnessed ingestion daily), keep some financial stability and make plans for the future. While this system has its share of abusers, the theory is sound.
In the case of medical marijuana, we try to remove opioids in a less proven method perhaps, and use a CBD/TCH combination to deal with pain in a way that has shown to work, even though we still have much to learn about long-term effects. Compounding can be included here as well, as studies have demonstrated and I have personally seen a regular pattern of reduced oral medications for pain when topical compounded products are introduced.
These demonstrate a practise we have shown in modern medicine for “a pill for every ill.” This is your symptom so this is your medication. In our defense we do try to project wellness campaigns into our profession surrounding eating right and physical activity—both with huge potential benefits. We actively run screening programs for cholesterol and blood glucose—again, often in free clinic formats without much evidence to back up clinical outcomes, such as death rate or disease prevention. This is all in the hope of reminding people to think about their health.
We have all pursued prevention programs in our pharmacies in one way or another. I removed sugary beverages a few years ago (a public health campaign that still resonates with my store today). I filmed a 40-minute healthy grocery shopping tour for YouTube for anyone to watch for free, and I have also done the blood pressure and glucose/cholesterol clinics in my store. In an era where evidence-based practitioners are claiming random screening in healthy populations proves questionable benefit, we push on despite costs to our businesses in both time and money.
What about the patient with either an acute need for a strong pain reliever or the one who is the long-term pain patient? You must be living under a rock if this hasn’t caused you to stop and think about where this patient will be in a few years (especially if they are not handled properly by both you and their doctor). Every time you fill a methadone prescription should make you think even harder. Why do we go through the trouble to screen for other diseases and prevent health complications while at the same time filling an opioid prescription while thinking “is this patient early for their refill?” Most of us have spent more time talking to a diabetic patients about their health than an oxycodone user about where their health is going. Is the potential impact of where that opioid patient could be headed any less drastic than the diabetic patient if not monitored properly? Even the patient on regular naproxen is probably not on our radar as someone who may get switched to an opioid and develop misuse issues down the road.
There are many responsible narcotic users out there who just don’t seem to be heading for any addiction or misuse problems. These patients are no less important when it comes to our vigilance though. We have tools available to us to help screen out those who are more likely to misuse. None of these tools are scientifically proven but they are based on our experience with various patient groups with opioids.
Realistically, any pain patient requires more time than the average patient even from day one. As specialized as methadone is today, it has become a regular fill commodity where a hundred or more patients come in for a witnessed ingestion and leave. With these numbers, there isn’t much time for a ”sit down” with each and every one. In stores with a more realistic number of patients, such as 10-20, it is conceivable that pharmacy staff is able to discuss how therapy is going each time, if they are showing subtle signs of drug use. A more one-on-one environment that isn’t rushed might bring out other signs of sub par therapy, drug diversion and other misuse.
If third-party payers reimbursed for such a specialized service, it would improve health outcomes in the long run. Each patient should be interviewed with each renewal of their opioid and as an initial consultation. Pharmacists are in the best place to detect misuse. A patient that is yawning or restless in front of you, or perhaps agitated during the med review, may be showing signs of withdrawal from an opioid and could be a patient who is taking other sources of opiates along with their prescription. Urine drug testing should be discussed as a possibility early on with treatment as well so that it doesn’t offend patients later on when they are suspected of misuse.
It is estimated that 22% of patients will discontinue opioid therapy due to side effects. This may involve dose-limiting side effects that would require a dose reduction or even a discontinuation of the medication. This may include sedation, which should be assessed with high opioid doses (especially more than 200mg oral morphing equivalents) and with each dose increase. Although this will often resolve itself with tolerance, if suspected it should be monitored closely. Asking a patient to return to the pharmacy within a few hours after a dose may help.
Cognitive dysfunction follows the same warnings of dose increase and high dose as with sedation but can be trickier to pick out unless you take time to speak to the patient for a few minutes. It involves cloudy thinking, poor memory and diminished concentration. As with sedation, reducing the dose, discontinuing the drug or opioid rotation can help. Opioid-induced hyperalgesia is a side effect where this specialty service proves its worth. Again it tends to occur at higher doses and is a phenomenon where the pain threshold seems to drop, giving an increased sensitivity to pain as the opioid dose increases. Instead of a knee jerk increase in opioid dose, the dose should actually be tapered or a COX-2 inhibitor can be given concurrently. It has also been recommended that an NMDA receptor antagonist like Ketamine be tried. Quite often this molecule is used in our pain compounding.
A potentially serious side effect that can occur with opioids is sleep apnea, possibly due to the effect on sleep architecture. This may affect up to 30% of all patients on chronic opioid therapy and can significantly exacerbate a pre-existing sleep apnea condition. This is why it can be helpful for the partner of the patient to come with them to the interview with each fill. Extra information may be gleaned from this type of environment. Respiratory depression is a commonly known side effect of opioid use, however tolerance develops rather quickly and is often a problem only with patients with pulmonary disease like COPD or asthma. It can result in limiting the dose in these patients especially at higher doses.
Constipation, nausea, vomiting, dry mouth, pruritis, urinary retention, myoclonus, hormonal effects, immune suppression, and weight gain/sugar craving are all important side effects that should be addressed and monitored. It is difficult to do all of this with a typical prescription handout at the counter. Of course, the most important effect to monitor is addiction. Although the risk of this is low, it is still a real possibility and constant vigilant monitoring is important to cover your bases.
Tapering doses has become popular with recent warnings to keep patients below 90 oral morphine equivalents. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain strongly recommends a coordinated multidisciplinary collaboration approach that involves several health professionals that are readily accessible to the physician. The Nova Scotia College of Pharmacists’ registrar Bev Zwicker released a communication to its members on June 26 explaining that the College of Physicians and Surgeons of Nova Scotia warning that the tapering of opioids needs to be done sensitively, collaboratively and with realistic expectations. It also confirmed that rapid withdrawal could be dangerous if done too quickly and that these high- -dose patients cannot be abandoned. These guidelines need to be reviewed by all involved especially pharmacists. Tapering should be considered if there are dose-limiting side effects that are intolerable, if the opioid trial is failed, if the pain has resolved itself, or if there is evidence of addiction or diversion. Most of these tapers are voluntary but the decision may be made by the physician unilaterally. Assessing the patient during the taper requires close monitoring for withdrawal symptoms.
This year, The Journal of the American Pharmacist Association published a paper where a pharmacist-led opioid exit plan for acute postoperative pain management can have benefits when involved at the point of admission, during the post operative recovery period and on discharge. A 2013 BMJ Open paper outlined an RCT where regular GP care was compared to pharmacist-led management of chronic pain and demonstrated improved pain outcomes with the pharmacist-led management.
A 2014 study involving a pharmacist-initiated intervention trial in osteoarthritis showed that patients experience quantifiable benefits from interprofessional collaboration among pharmacists, physicians and physiotherapists. We have also seen pharmacists’ involvement in the co-management of acute pain and substance use disorder improves patient safety and pain control.
Creating your own niche market where you are the go to pharmacy for beneficial outcomes in acute and chronic pain patients becomes key where you are trying to prevent opioid misuse and abuse. It starts with one on one time with the pharmacist and patient each time they come into your pharmacy. It can make your pharmacy the safe place for patients, from their initial prescription for pain to managing a chronic condition while avoiding addiction. Hopefully a patient or their third-party plan would pay for that service.
Ware et al CMAJ 2010; 182(4)
AMN The Prescribing Course—Safe Opioid Prescribing for Chronic Non-Cancer Pain 1st Ed Oct 2014 MacDougall/Fraser
Bruhn H, Bond CM, Elliott AM, et al. Pharmacist-led management of chronic pain in primary care; results from a randomized controlled exploratory trial. BMJ Open 2013;3:e002361
Marra, CA et al Cost-Utility Analysis of a Multidisciplinary Strategy to Manage Osteoarthritis of the Knee: Economic Evaluation of a Cluster Randomized Controlled Trial Study. Arthrit Care Res. 2014 June; 66 (6): 810-816
Andrews LB, et al, Implementation of a pharmacist-driven pain management consultation service for hospitalized adults with a history of substance abuse. Int J Clin Pract. 2013 Dec; 67 (12): 1342-9.